Denali Therapeutics Inc. Common Stock (DNLI) Ownership & Trading Activity
Institutional holders, insider transactions, and congressional trades for DNLI. 13F holdings as of 2026-06-30.
Top Institutional Holders
| Institution | Shares | Value | Change |
|---|---|---|---|
| T. Rowe Price | 19,315,112 | $497M | INCREASED |
| BlackRock | 14,026,413 | $361M | INCREASED |
| Vanguard | 13,996,606 | $360M | INCREASED |
| Baillie Gifford | 11,960,230 | $308M | DECREASED |
| State Street | 7,049,304 | $181M | INCREASED |
Recent Insider Trades
| Insider | Type | Shares | Value | Date |
|---|---|---|---|---|
| Peter Scott Chin (Chief Medical Officer) | SELL | 1,654 | $37K | 2026-09-04 |
| Nancy Thornberry (Director) | SELL | 615 | $15K | 2026-09-02 |
| Nancy Thornberry (Director) | SELL | 10,824 | $247K | 2026-09-02 |
| Alexander O. Schuth (COFO and Secretary) | SELL | 2,768 | $65K | 2026-09-01 |
| Ryan J. Watts (President and CEO) | GIFT | 32,220 | 2026-08-12 |
Full institutional holdings, insider history, and congressional trades for Denali Therapeutics Inc. Common Stock on SentiSense.